Monitor for financing announcements (equity offering, partnership, or licensing deal) to fund the DUBLIN-4 Phase 3 trial, as the $6.5M cash position is insufficient. The next catalyst is likely a DUBLIN-4 trial initiation update or a capital raise event, which could drive significant volatility given the $41M market cap.
Price Chart
Executive Summary
BeyondSpring reported Q2 2026 net loss of $1.8M from continuing operations, essentially flat YoY, with no revenue. The key catalyst is the clinical progress of Plinabulin, including updated Phase 2 data showing a 58% two-year OS rate in post-ICI NSCLC and preclinical ADC combination data, alongside a leadership transition to advance the confirmatory DUBLIN-4 Phase 3 study. With only $6.5M in cash and a cash burn of ~$6M in H1 2026, the company faces significant financing risk to initiate the planned 442-patient trial, making the stock's movement dependent on pipeline milestones and capital raises rather than financial results.
Key Financial Metrics
Key Facts
- Q2 2026 net loss from continuing operations was $1.8M, compared to $1.9M in Q2 2025.
- Cash, cash equivalents, and short-term investments were $6.5M as of June 30, 2026, down from $12.6M at year-end 2025.
- Updated Phase 2 data at ASCO 2026 showed a 58% two-year OS rate in post-ICI metastatic NSCLC.
- Preclinical AACR 2026 data showed Plinabulin improved complete response rates and tolerability with ADC regimens.
- Leadership transition effective July 1, 2026: Min Qiu appointed CEO, Na Li appointed CFO, Dr. Jen Majeti appointed Vice Chairman.
- The DUBLIN-4 confirmatory Phase 3 study (442 patients) is the lead clinical priority, with OS as primary endpoint.
Financial Impact
Net loss from continuing operations of $1.8M in Q2 2026, flat YoY; cash burn of ~$6.1M in H1 2026; cash runway of ~6 months at current burn rate.
Risk Factors
- Cash runway of ~6 months at current burn rate; likely need for dilutive financing to initiate DUBLIN-4 trial.
- Clinical risk: DUBLIN-4 is a confirmatory Phase 3; failure would severely impair Plinabulin's value.
- Nasdaq continued listing risk if share price remains low; company has history of reverse stock splits.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4600 (−28.68%) |
Oct 2, 2026 24d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4600 (+41.48%) |
Sep 29, 2026 27d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4600 (−40.51%) |
Sep 29, 2026 27d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4600 (+40.51%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4600 (+37.84%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4600 (−25.58%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4600 (−35.35%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4600 (−35.35%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4600 (−73.10%) |
Jun 2, 2026 20w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4600 (−72.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers